"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...

Additionally, the semaglutide 2.4-mg arm experienced significant reductions in systolic blood pressure vs the placebo arm across these trials (P ≤ .0016); between-group differences also varied ...

GLP-1 patches, topical adhesive patches worn on your arm or abdomen that claim to deliver natural weight-loss revving ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

By Tarun Sai Lomte Study reveals how semaglutide not only aids in weight loss but also offers a surprising defense against severe infections, including COVID-19, in at-risk populations. Study: The ...

The total eGFR slope was significantly less steep in the semaglutide than placebo arm (-0.78 vs -1.17), for a 0.39 mL/min/1.73 m 2 per year lower slope for the semaglutide group.

Semaglutide improved metabolic dysfunction–associated steatotic liver disease (MASLD) among people living with HIV, and in some cases resolved it completely, according to results from the SLIM ...

Early Friday, Novo shared full results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney ...

This builds on previous findings of a phase 2 trial where 59% of patients taking semaglutide saw this outcome compared with 17% taking placebo (P < .001). 3 Meanwhile, reduced liver fibrosis ...

In a small study of patients with type 1 diabetes using an automated insulin delivery system, semaglutide improved glucose control vs. placebo, researchers reported at the European Association for ...

Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings ...